Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.Bioorganic & Medicinal Chemistry Letters|January 5, 2002
Mixed lineage kinase activity of indolocarbazole analoguesChikara Murakata, Masami Kaneko, George Gessner, et al.Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.Cell Chemical Biology|November 20, 2018
Covalent Docking Identifies a Potent and Selective MKK7 InhibitorAmit Shraga, Evgenia Olshvang, Natalia Davidzohn, et al.Bioorganic & Medicinal Chemistry Letters|March 1, 2008
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinasesReddeppareddy Dandu, Allison L Zulli, Edward R Bacon, et al.Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.JCI Insight|April 3, 2025
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasiaJacqueline H Starrett, Clara Lemoine, Matthias Guillo, et al.Journal of Medicinal Chemistry|June 4, 2011
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonistRobert L Hudkins, Rita Raddatz, Ming Tao, et al.The Journal of Pharmacology and Experimental Therapeutics|October 18, 2011
CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activitiesRita Raddatz, Robert L Hudkins, Joanne R Mathiasen, et al.Journal of Medicinal Chemistry|December 4, 2003
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055Diane E Gingrich, Dandu R Reddy, Mohamed A Iqbal, et al.Pageof 5